



Immunity to SARS-CoV-2: Humoral and Cellular Immune Response

Guest Editor:

Dr. Cinzia Giagulli

Section of Microbiology,
Department of Molecular and
Translational Medicine,
University of Brescia, 25123
Brescia, Italy

Deadline for manuscript
submissions:
closed (15 August 2023)

Message from the Guest Editor

In the effort to control SARS-CoV-2 transmission and COVID-19 infections, global public health agencies are aiming to increase population immunity by vaccination. The introduction of highly effective vaccines has provided an intervention reducing the risk and severity of SARS-CoV-2 infection.

Thus, in this Special Issue, we aim to explore both humoral and T cell responses to vaccination and people undergoing various pharmacological treatments, and the mechanisms behind them.

Keywords:

- adaptive immunity against SARS-CoV-2
- T cell immunity to SARS-CoV-2
- humoral and cellular immune response
- antibody





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI